drugset
drugset / Trial / NCT06527534

Filgotinib Effect on Proteomic Profile and Micro-RNA Expression in Patients With Active Rheumatoid Arthritis (RA)

NCT06527534 ↗

Phase 4 Recruiting 30 enrolled University of Verona
RandomizedParallel-groupOpen-labelTreatment

Summary

Purpose: The study aims to investigate how Filgotinib affects proteins and micro-RNA in the blood of patients with rheumatoid arthritis. This could help understand its impact on inflammation and bone health in these patients. Study Design: This is a single-center, prospective randomized study.

Timeline

Start
2024-07-15
Primary completion
2025-07-15
Completion
2025-09-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Adalimumab Monoclonal antibody 40 mg Subcutaneous
Subject Filgotinib Small molecule 200 mg Oral

Indications

rheumatoid arthritis